Alnylam Pharmaceuticals Ownership & Insider Activity

Alnylam Pharmaceuticals (ALNY) institutional and insider ownership, recent insider transactions and ownership breakdown.

Insiders own 0.5% of shares outstanding. Institutional investors hold 92.9%.

Shares Outstanding

133.809M

Shares Float

100.437M

Insider Shares Owned

675.825K

Insider % Owned

0.5%

Institutional Shares Held

124.300M

Institutional % Held

92.9%

Ownership Breakdown

Net Insider Activity by Month

Alnylam Pharmaceuticals Insider Transactions (Last 6 Months)

Date	Insider	Title	Type	Shares	Price	Value
Jun 1, 2026	David E.I. Pyott	DIRECTOR	SELL-OPTIONS	—	$299.18	$1.1M
Apr 2, 2026	Melissa McLaughlin	CHIEF HUMAN RESOURCES OFFICER	SELL	3.910K	$325.92	$1.3M
Mar 4, 2026	Pushkal Garg	EVP CHIEF R&D	SELL	4.713K	$323.53	$1.5M
Mar 4, 2026	Yvonne Greenstreet	CHIEF EXECUTIVE OFFICER	SELL	2.933K	$323.08	$948K
Mar 4, 2026	Jeffrey V Poulton	EVP, CHIEF FINANCIAL OFFICER	SELL	2.468K	$323.08	$797K
Mar 4, 2026	Tolga Tanguler	EVP, CHIEF COMMERCIAL OFFICER	SELL	2.309K	$323.08	$746K
Mar 4, 2026	Kevin Fitzgerald	CSO & EVP, HEAD RESEARCH	SELL	1.291K	$323.54	$418K
Mar 2, 2026	Jeffrey V Poulton	EVP, CHIEF FINANCIAL OFFICER	GRANT	2.563K	$327.65	$723K
Mar 2, 2026	Pushkal Garg	EVP CHIEF R&D	GRANT	1.277K	$323.63	$1.1M
Mar 2, 2026	Kevin Fitzgerald	CSO & EVP, HEAD RESEARCH	GRANT	438.000	$323.62	$1.1M
Mar 2, 2026	Tolga Tanguler	EVP, CHIEF COMMERCIAL OFFICER	GRANT	3.171K	$327.65	$524K
Mar 2, 2026	Yvonne Greenstreet	CHIEF EXECUTIVE OFFICER	GRANT	7.045K	$327.65	$2.2M
Feb 27, 2026	Pushkal Garg	EVP CHIEF R&D	SELL	2.719K	$331.34	$1.5M

Date	Member	Party	Chamber	Action	Amount
May 12, 2025	Jefferson Shreve	R	House	S	$15,001 - $50,000
Jan 29, 2024	Josh Gottheimer	D	House	S	$1,001 - $15,000
Jan 11, 2024	Josh Gottheimer	D	House	P	$1,001 - $15,000
Dec 11, 2023	Josh Gottheimer	D	House	S	$1,001 - $15,000